语言特征是否有助于对神经退行性疾病的分类? - 一个探索性研究研究
Yasuhiro Watanabe1, Mika Uemoto1, Mika Otsuki2
1Division of Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Japan.
Internal medicine (Tokyo, Japan)
|June 26, 2025
概括
日本语言屏幕 (JLS) 有助于识别神经退行性疾病 (如阿尔茨海默氏症和帕金森症) 中的语言缺陷. 虽然有用,但它在区分特定条件方面存在局限性.
科学领域:
- 神经语言学是一种神经语言学.
- 神经退行性疾病 神经退行性疾病
- 临床评估 临床评估
背景情况:
- 在神经退行性疾病中评估语言症状存在挑战,因为其呈现方式多样化.
- 日本语言的独特特点需要专门的评估工具.
研究的目的:
- 开发和验证日本语言屏幕 (JLS),用于评估11个不同的语言方面.
- 识别特定于阿尔茨海默病 (AD),帕金森病 (PD),肌缩侧面硬化症 (ALS) 和渐进性上核性 (PSP) 的语言症状.
- 确定JLS能够区分这些神经退行性疾病和健康对照 (HC) 的能力.
主要方法:
- 该JLS对168名参与者进行了管理,包括患有AD,PD,ALS,PSP和HC的患者.
- 评估的语言功能包括语法障碍,发音和表达障碍 (IAP),单词回忆,语法理解,语解释和写作.
- 数据分析的重点是识别疾病组之间的表现差异,以及组与HC之间的差异.
主要成果:
- 根据总分数,JLS有效地将参与者的语言状态分类为正常或受损.
- 渐进性上核性麻 (PSP) 患者表现出比AD患者更严重的语言缺陷,尽管认知得分相似.
- 与HC相比,阿尔茨海默氏病 (AD) 和PSP组在超过一半的JLS项目中显示出显著的损伤,PSP受影响更大. 患有ALS的患者在IAP和写作方面有缺陷,特别是在语理解方面. 帕金森病 (PD) 的表现与HC的表现相当.
结论:
- 日本语言屏幕 (JLS) 是理解神经退行性疾病语言症状的宝贵工具.
- 联合语言测试显示了在识别与不同神经疾病相关的特定语言配置文件方面的潜力.
- 该研究表明,JLS对所有研究的神经退行性疾病的最终分类和区分能力存在局限性.
相关概念视频
Neural Regulation
40.3K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.3K
Classification of Neurotransmitters
3.7K
Neurotransmitters play a crucial role in the communication between neurons in the autonomic nervous system. Neurons in the autonomic nervous system can be cholinergic or adrenergic depending on the neurotransmitters synthesized. Cholinergic neurons use acetylcholine as their primary neurotransmitter. This includes all the preganglionic fibers of the sympathetic and pre- and postganglionic fibers of the parasympathetic nervous systems. In addition, neurons of the somatic nervous system also use...
3.7K
Alzheimer's Disease: Overview
678
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
678
Parkinson's Disease: Overview
718
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
718
Disorders of the Nervous Tissue
1.6K
Nervous tissue is a vital component of the human body's communication system, enabling us to perceive and respond to stimuli. However, like all other tissues, it is vulnerable to disorders and diseases that can significantly impact our neurological functioning.
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
1.6K
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265


